Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylphenylsulfone SCHEMBL1332357 | 0.87 | PTGS2 (0.62) | PTGS2ENPP2TSHRSMN1; SMN2HTR6 | |
| Methylphenylsulfone SCHEMBL78253 | 0.87 | PTGS2 (0.62) | PTGS2ENPP2TSHRSMN1; SMN2HTR6 | |
| Methylphenylsulfone SCHEMBL5499087 | 0.85 | PTGS2 (0.60) | PTGS2ENPP2TSHRSMN1; SMN2HTR6 | |
| Methylphenylsulfone SCHEMBL561404 | 0.83 | PTGS2 (0.54) | PTGS2ENPP2TSHRSMN1; SMN2HTR6 | |
| Methylphenylsulfone SCHEMBL28097901 | 0.82 | PTGS2 (0.58) | PTGS2ENPP2TSHRSMN1; SMN2HTR6 | |
| Methylphenylsulfone SCHEMBL28046614 | 0.82 | PTGS2 (0.58) | PTGS2ENPP2TSHRSMN1; SMN2HTR6 | |
| Methylphenylsulfone SCHEMBL28158010 | 0.82 | PTGS2 (0.58) | PTGS2ENPP2TSHRSMN1; SMN2HTR6 | |
| Methylphenylsulfone SCHEMBL28288198 | 0.82 | PTGS2 (0.58) | PTGS2ENPP2TSHRSMN1; SMN2HTR6 | |
| Methylphenylsulfone SCHEMBL11042562 | 0.81 | PTGS2 (0.52) | PTGS2ENPP2TSHRSMN1; SMN2AKR1C2 | |
| Methylphenylsulfone SCHEMBL28624441 | 0.81 | PTGS2 (0.52) | PTGS2ENPP2HTR6PSIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301988-A1 | INHIBITORS OF SARS COV-2 INFECTION AND USES THEREOF | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-09-28 | — | — | US | disclosed |
| EP-4203957-A2 | INHIBITORS OF SARS COV-2 INFECTION AND USES THEREOF | The Texas A&M University System (US) | 2023-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301988-A1 | INHIBITORS OF SARS COV-2 INFECTION AND USES THEREOF | CTSV, ACE2, CTSL | PTGS2 1024/4885ENPP2 1735/4885TSHR 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.